Fas/FasL in the immune pathogenesis of severe aplastic anemia

Genetics and Molecular Research

Volumn 13, Issue 2, 2014, Pages 4083-4088

  Liu, C Y ^a   Fu, R ^a   Wang, H Q ^a   Li, L J ^a   Liu, H ^a   Guan, J ^a   Wang, T ^a   Qi, W W ^a   Ruan, E B ^a   Qu, W ^a   Wang, G J ^a   Wu, Y H ^a   Song, J ^a   Xing, L M ^a   Shao, Z H ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Fas FasL; Severe aplastic anemia

Indexed keywords

CD14 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CELL PROTEIN; FAS ANTIGEN; FAS LIGAND; PROTEIN GLYCOA; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CD45 ANTIGEN; CD8 ANTIGEN; FAIM PROTEIN, HUMAN; FASLG PROTEIN, HUMAN; PTPRC PROTEIN, HUMAN;

ADOLESCENT; ADULT; APLASTIC ANEMIA; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMATOPOIETIC CELL; HUMAN; IMMUNOPATHOGENESIS; MALE; PROTEIN EXPRESSION; BIOSYNTHESIS; BONE MARROW CELL; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTIGENS, CD34; ANTIGENS, CD45; ANTIGENS, CD8; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE MARROW CELLS; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELLS; HUMANS; MALE;

EID: 84901782734     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.May.30.3     Document Type: Article

References (9)

1. Bohana-Kashtan O and Civin CI (2004). Fas ligand as a tool for immunosuppression and generation of immune tolerance. Stem Cells 22: 908-924.
2. Ehrenschwender M and Wajant H (2009). The role of FasL and Fas in health and disease. Adv. Exp. Med. Biol. 647: 64-93.
3. HBCMA (2010). Aplastic anemia diagnosis and treatment expert consensus. Hematology Branch of the Chinese Medical Association Red Blood Cell Disease (Anemia) Study Group. Chin. J. Hematol. 31: 790-792.
4. Locasciulli A, Oneto R, Bacigalupo A, Socie G, et al. (2007). Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 92: 11-18.
5. Otsuki T, Hayashi H, Nishimura Y, Hyodo F, et al. (2011). Dysregulation of autoimmunity caused by silica exposure and alteration of Fas-mediated apoptosis in T lymphocytes derived from silicosis patients. Int. J. Immunopathol. Pharmacol. 24: 11S-16S.
6. Pryczynicz A, Guzinska-Ustymowicz K and Kemona A (2010). Fas/FasL expression in colorectal cancer. An immunohistochemical study. Folia Histochem. Cytobiol. 48: 425-429.
7. Randhawa SR, Chahine BG, Lowery-Nordberg M, Cotelingam JD, et al. (2010). Underexpression and overexpression of Fas and Fas ligand: a double-edged sword. Ann. Allergy Asthma Immunol. 104: 286-292.
8. Shao ZH (2010). Standardized diagnosis and treatment of aplastic anemia. Chin. J. Intern. Med. 30: 311-313.
9. Zhang ZN and Shen T (2007). Blood Disease Diagnosis and Efficacy Standards. 3rd edn. Science Press, Beijing.